CJC-1295 and Ipamorelin
Small human studies of each compound's hormone effects. No human trials of the combination.
At a glance. Two compounds that push growth hormone release through different routes, usually combined in one vial. Sold by AVERON as the CJC-IPA blend.
Written and maintained by the AVERON Research Desk · Last reviewed September 2026
What they are
CJC-1295 is a modified version of growth-hormone-releasing hormone, the signal that tells the pituitary gland to release growth hormone. It exists in two forms, and the difference matters:
- CJC-1295 with DAC carries a chemical attachment that binds it to proteins in the blood, so it lasts for days.
- CJC-1295 without DAC, also called modified GRF (1-29), lacks that attachment and lasts a much shorter time, producing a short pulse of growth hormone release.
Ipamorelin is a small peptide of five amino acids that acts on a different receptor, the one normally activated by the hunger hormone ghrelin. It also triggers growth hormone release, but through a separate pathway.
Because the two work through different routes, they are commonly combined. AVERON's blend contains CJC-1295 without DAC and ipamorelin.
What researchers study them for
Growth hormone deficiency, body composition, sleep and recovery.
What the research shows
The main human study of CJC-1295 was published by Sam Teichman and colleagues in the Journal of Clinical Endocrinology & Metabolism in 2006. In healthy adults, a single injection of CJC-1295 with DAC raised growth hormone levels several-fold for six days or more, and raised IGF-1 for more than a week.
Ipamorelin was described by Kirsten Raun and colleagues in the European Journal of Endocrinology in 1998 as the first selective growth hormone secretagogue. In their animal studies, it released growth hormone without the rise in cortisol seen with some earlier compounds of its type.
The important gap: the published human study of CJC-1295 used the DAC version. The version without DAC, which is what our blend contains, has no comparable published trial. And no trial has tested CJC-1295 and ipamorelin together.
What it does not do, and what is not known
- It is not growth hormone, and it does not produce the effects of growth hormone treatment. It stimulates the body's own release.
- It does not build muscle. Resistance training and adequate protein build muscle.
- The main human study used a different form of CJC-1295 from the one in our blend.
- The combination has never been tested in a human trial.
- Neither compound is an approved medicine, so there is no long-term safety data in people.
Adverse effects reported in research
In the human study of CJC-1295 with DAC, reported effects included reactions at the injection site and transient flushing. Raising growth hormone and IGF-1 in general is associated with water retention, tingling in the hands and changes in blood sugar.
Regulatory and anti-doping status
Regulatory: Neither compound is approved as a medicine anywhere.
Anti-doping: Both are named on WADA's Prohibited List under category S2: CJC-1295 as a growth-hormone-releasing hormone analogue, and ipamorelin as a growth hormone secretagogue. Prohibited at all times in tested sport.
At AVERON
Supplied as research-grade material, the CJC-IPA blend: CJC-1295 without DAC 5 mg and ipamorelin 5 mg, co-lyophilized in one 10 mg vial.
Independent lab report: 105140_N2WTIRKQ1D9A
Frequently asked questions
Doses mentioned on this page are the arms of published studies, given to describe their results. They are not guidance.
Sources
- Teichman SL, Neale A, Lawrence B, et al.. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 2006;91(3):799–805. Link
- Raun K, Hansen BS, Johansen NL, et al.. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 1998;139(5):552–561. Link
- World Anti-Doping Agency. The Prohibited List. WADA. Link

